CRISPR Therapeutics (NASDAQ:CRSP) Issues Earnings Results

CRISPR Therapeutics (NASDAQ:CRSP) issued its quarterly earnings results on Thursday. The company reported ($1.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($0.22), FiscalAI reports. The firm had revenue of $0.86 million for the quarter, compared to analyst estimates of $4.72 million. CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.69%. The firm’s revenue for the quarter was down 97.8% compared to the same quarter last year. During the same quarter last year, the business posted ($1.01) earnings per share.

CRISPR Therapeutics Trading Up 8.5%

CRSP stock opened at $53.07 on Friday. CRISPR Therapeutics has a one year low of $30.04 and a one year high of $78.48. The firm has a 50-day moving average of $54.22 and a two-hundred day moving average of $57.37. The firm has a market capitalization of $5.06 billion, a PE ratio of -8.14 and a beta of 1.72.

CRISPR Therapeutics News Roundup

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Casgevy commercial momentum—management highlighted that Casgevy generated about $54M in Q4 and $116M for full‑year 2025, supporting the view that adoption for the company’s approved SCD/TDT therapy is expanding and producing meaningful sales. CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens
• Positive Sentiment: Analyst upgrade/price‑target lift—Needham raised its price target to $82 and maintained a Buy rating, signaling institutional conviction that shares have upside on continued commercial execution. CRSP Price Target Raised by Needham
• Neutral Sentiment: Official business update and results—CRISPR published its Q4 and full‑year 2025 results and a business update emphasizing pipeline progress and upcoming label expansion plans; this is informative for longer‑term thesis but contains limited near‑term financial guidance. CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Positive retail narrative—an upbeat Fool feature framed the company as a “blastoff‑ready” biotech pick for 2026, which can boost retail buying interest but is opinion‑driven. The Blastoff-Ready Biotech Stock You’ll Kick Yourself for Not Buying in 2026
• Neutral Sentiment: Short‑interest data appears anomalous—recent reports show short interest listed as 0 shares (likely a reporting/data issue), so short‑interest signaling is unclear and should be treated cautiously.
• Negative Sentiment: Quarterly miss and wider loss—CRSP reported Q4 EPS of ($1.37) versus consensus ($1.15) and revenue of $0.86M versus $4.72M expected; revenue fell sharply year‑over‑year, underscoring near‑term financial pressure and a negative margin/earnings backdrop. CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 60,000 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $60.23, for a total transaction of $3,613,800.00. Following the sale, the chief executive officer owned 134,201 shares in the company, valued at $8,082,926.23. The trade was a 30.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada boosted its position in shares of CRISPR Therapeutics by 28.2% in the first quarter. Royal Bank of Canada now owns 142,696 shares of the company’s stock worth $4,856,000 after buying an additional 31,392 shares during the period. AQR Capital Management LLC purchased a new stake in CRISPR Therapeutics in the 1st quarter worth about $861,000. Woodline Partners LP lifted its stake in CRISPR Therapeutics by 34.3% in the 1st quarter. Woodline Partners LP now owns 136,483 shares of the company’s stock worth $4,645,000 after acquiring an additional 34,883 shares in the last quarter. Prudential Financial Inc. acquired a new stake in CRISPR Therapeutics during the 2nd quarter worth about $237,000. Finally, Invesco Ltd. grew its stake in CRISPR Therapeutics by 138.4% during the 2nd quarter. Invesco Ltd. now owns 66,648 shares of the company’s stock valued at $3,242,000 after acquiring an additional 38,691 shares in the last quarter. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently issued reports on CRSP. Robert W. Baird lowered their target price on CRISPR Therapeutics from $52.00 to $44.00 and set a “neutral” rating on the stock in a report on Tuesday, November 11th. Evercore ISI restated an “outperform” rating and set a $74.00 price objective on shares of CRISPR Therapeutics in a research report on Friday. Bank of America lowered their price objective on shares of CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating on the stock in a research note on Thursday, January 22nd. Chardan Capital set a $76.00 target price on shares of CRISPR Therapeutics in a research note on Saturday. Finally, Citizens Jmp reduced their target price on shares of CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating for the company in a report on Friday, January 30th. Eleven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $67.35.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.